Clalit offers genetic test for breast cancer patients

Oncologists do not recognize Oncotype DX genetic test as 'standard of care'.

February 13, 2006 22:34
1 minute read.
Clalit offers genetic test for breast cancer patients

breast cancer 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Clalit Health Services will pay $4,000 to test every woman member with breast cancer who is suited to the Oncotype DX genetic test to determine whether their genetic profile gives them the potential to benefit from special chemotherapy. The largest health fund said that it expects between 250 and 300 Clalit members who meet its criteria will require and want such testing, in which a tissue sample removed in surgery is sent abroad. The test has not been included in the Health Ministry's basket of health services, although it was previously a candidate and rejected. Clalit director-general Zev Vurmbrand called the voluntary decision "a breakthrough and good news for women with breast cancer." Clalit said it was the first health maintenance organization outside the US to offer the Oncotype DX test to its members. The benefit will be available to all "suitable" women with breast cancer in Clalit, and not only to those who pay for its supplementary health insurance. More than 1,000 Clalit members contract breast cancer each year. Clalit said the genetic test can rule out those patients who don't need extra chemotherapy and determine who will benefit from it. It determines the biological changes in the tumor and their influence on growth, ability of the tumor to penetrate blood vessels and lymph glands and its ability to metastasize to other parts of the body. The test looks at the expression of 16 genes connected to breast malignancies and uses five other genes for quality control. These genes were chosen from among a databank of 250. However, asked to comment, a leading oncology expert who specializes in the field said that the Oncotype DX test is "not the treatment standard in the Western world" and not recommended. Instead, if Clalit has the money, it should be invested in other medical technologies for cancer." The spokesman for Maccabi Health Services, the second largest health funds that often boasted about its voluntary introduction of expensive medications and other technologies into its own basket of services that its competitors lacked, said the Oncotype DX is not one of those it has decided to offer to patients at this stage. "We prefer to spend our resources on other proven lifesaving technologies for breast cancer such as Herceptin," he said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia